Inogen Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Inogen de 29.2% y 4.1% por año respectivamente. Se prevé que el BPA crezca en un 34.7% al año. Se espera que la rentabilidad financiera sea de -28.5% en 3 años.

Información clave

29.2%

Tasa de crecimiento de los beneficios

34.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.2%
Tasa de crecimiento de los ingresos	4.1%
Rentabilidad financiera futura	-28.5%
Cobertura de analistas	Low
Última actualización	29 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01

Recent updates

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Apr 13

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Feb 01

Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Sep 20

Inogen: Structural, Supply Chain Headwinds Remain

Sep 13

Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M

Aug 04

Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds

Jun 14

At US$35.28, Is It Time To Put Inogen, Inc. (NASDAQ:INGN) On Your Watch List?

Apr 03

Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story

Mar 31

Is There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 28% Undervaluation?

Mar 09

Inogen: Capacity Constraints Cloud Post Pandemic Potential

Jan 06

Is Inogen, Inc. (NASDAQ:INGN) Potentially Undervalued?

Dec 09

Returns On Capital At Inogen (NASDAQ:INGN) Paint A Concerning Picture

Nov 08

Supply Chain Issues Knock Inogen Back, But Underlying Growth Is Encouraging

Aug 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:INGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	358	-45	-24	20	2
12/31/2025	338	-52	-27	10	4
12/31/2024	324	-58	N/A	3	4
12/31/2023	316	-102	-30	-3	N/A
9/30/2023	328	-133	-43	-16	N/A
6/30/2023	349	-96	-55	-27	N/A
3/31/2023	369	-90	-50	-26	N/A
12/31/2022	377	-84	-59	-38	N/A
9/30/2022	366	-50	-36	-16	N/A
6/30/2022	353	-28	-31	-9	N/A
3/31/2022	351	-20	-20	3	N/A
12/31/2021	358	-6	0	24	N/A
9/30/2021	356	11	9	33	N/A
6/30/2021	337	-2	20	43	N/A
3/31/2021	307	-5	19	39	N/A
12/31/2020	308	-6	19	37	N/A
9/30/2020	313	-2	16	30	N/A
6/30/2020	331	6	29	38	N/A
3/31/2020	360	14	36	43	N/A
12/31/2019	362	21	34	41	N/A
9/30/2019	370	32	37	44	N/A
6/30/2019	373	42	34	43	N/A
3/31/2019	369	46	35	46	N/A
12/31/2018	358	52	47	60	N/A
9/30/2018	335	41	44	61	N/A
6/30/2018	309	32	49	64	N/A
3/31/2018	276	26	48	60	N/A
12/31/2017	249	21	50	60	N/A
9/30/2017	237	27	N/A	53	N/A
6/30/2017	222	25	N/A	44	N/A
3/31/2017	212	24	N/A	39	N/A
12/31/2016	203	21	N/A	31	N/A
9/30/2016	192	19	N/A	38	N/A
6/30/2016	179	17	N/A	41	N/A
3/31/2016	168	13	N/A	37	N/A
12/31/2015	159	12	N/A	38	N/A
9/30/2015	148	9	N/A	30	N/A
6/30/2015	136	9	N/A	21	N/A
3/31/2015	123	7	N/A	23	N/A
12/31/2014	113	5	N/A	16	N/A
9/30/2014	103	6	N/A	13	N/A
6/30/2014	94	3	N/A	15	N/A
3/31/2014	83	1	N/A	9	N/A
12/31/2013	75	0	N/A	13	N/A
9/30/2013	70	-3	N/A	13	N/A
6/30/2013	63	-4	N/A	9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que INGN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que INGN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que INGN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4.1% al año) de INGN crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.1% al año) de INGN crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: INGN se prevé que no sea rentable en 3 años.

Inogen Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Consensus revenue estimates decrease by 14%, EPS upgraded

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 53%

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Recent updates

New minor risk - Shareholder dilution

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024

Insider exercised options and sold US$54k worth of stock

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Market cap size

Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?

Inogen, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 14%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States

Inogen, Inc. Announces Board Changes

Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?

CEO, President & Director exercised options and sold US$130k worth of stock

Consensus EPS estimates fall by 53%

Full year 2022 earnings: EPS misses analyst expectations

Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023

Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Executive VP & CTO exercised options and sold US$53k worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth

Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Inogen: Structural, Supply Chain Headwinds Remain

CEO, President & Director exercised options and sold US$53k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Inogen Non-GAAP EPS of -$0.02 beats by $0.31, revenue of $103.38M beats by $2.74M

Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index

Inogen: Seasonal FCF, Tightening Margins, Supply Chain Headwinds

Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022

Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Price target decreased to US$44.00

High number of new and inexperienced directors

Inogen, Inc., Annual General Meeting, Jun 08, 2022

Inogen, Inc. Announces Management Changes

Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022

Now 22% undervalued

At US$35.28, Is It Time To Put Inogen, Inc. (NASDAQ:INGN) On Your Watch List?

High number of new and inexperienced directors

Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story

Is There An Opportunity With Inogen, Inc.'s (NASDAQ:INGN) 28% Undervaluation?

Now 23% undervalued

Inogen, Inc. Executive Changes

CEO, President & Director exercised options and sold US$378k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Now 21% undervalued after recent price drop

Consensus forecasts updated

Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc